Loading…
Hosted by MDS Foundation · 🇺🇸 US · EN · 13 episodes
Established thought leaders with verified media credentials.
This podcast series provides important up-to-the-minute information on MDS including diagnosis, treatment and clinical research. The explosion of information on MDS forces us to seek novel, alternative ways to distribute it. Podcasts gives us an easy and popular way to communicate this information in a short time.
MDS Foundation hosts MDS Professional Report, a health show with 13 episodes published.
This episode features Dr. Nikolaos Papadantonakis from the Winship Cancer Institute of Emory University and Dr. Amer Zeidan from the Yale School of Medicine, discussing research on Myelodysplastic Syndromes (MDS) present
![Pathogenesis and inflammaging in MDS [MDS Professional Report] episode artwork](https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/c8c843cc8c8e08a4761e7c633e0046c2.jpg)
Dr. Moshe Mittelman is hosting the world-leading expert Dr. Michael Savona and they have an attractive conversation on several mechanisms involved in the pathogenesis of MDS, including the interaction between genetics, i
![Treatment of lower-risk MDS [MDS Professional Report] episode artwork](https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/59731ffad6896313dd70ce957e619b02.jpg)
Prof. Uwe Platzbecker from Leipzig and Prof. Moshe Mittelman from Tel-Aviv in an interesting conversation on the various available therapeutic modalities for patients with lower-risk MDS.
![Treatment for Higher-risk MDS [MDS Professional Report] episode artwork](https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/474af5f93a7c919181979937a2ea20a4.jpg)
Prof. Nicolaus Kröger from Hamburg and Prof. Moshe Mittelman from Tel-Aviv, in a stimulating conversation on the various therapeutic modalities, including hematopoietic transplantation, in patients with higher-risk MDS.
![Update on Higher-Risk MDS - Lessons from 2023 ASH [MDS Professional Report] episode artwork](https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/6fb86eb9669a4d2de76fbe628d3c3231.jpg)
Dr. Nicolaos Papadantonakis from Emory Atlanta and Dr. Moshe Mittelman from Tel-Aviv, describe several updated abstracts from 2023 ASH with a special focus on Higher-risk MDs, and providing their take home messages.
Drs Nikolaos Papadantonakis of Emory, Atlanta, US, and Moshe Mittelman, Tel-Aviv, Israel, discuss trials presented in American Society of Hematology (ASH) 2023 meeting. They provide some data on luspatercept, imetelstat,
Prof. Rena Buckstein from Toronto, and Prof. Moshe Mittelman from Tel-Aviv discuss issues related to RBC transfusions, the hemoglobin threshold for transfusion and related quality of life issues.
Prof. Akiko Shimamura of Harvard Medical School, Boston, a world known expert of pediatric hematology discusses with Prof. Guillermo Sanz ,of Valencia and Prof. Moshe Mittelman, of Tel Aviv, the various aspects of bone m
Drs. Rafael Bejar (San Diego) and Moshe Mittelman (Tel Aviv) discuss several papers highlighting the role of genetics in MDS diagnosis, follow up and prediction of treatment. They also discuss the role of the newly appro
![MDS in ASH 2021 – Are we already in the molecular era? [MDS Professional Report] episode artwork](https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/6f4d6f2e2159220a3406f67f0e6f82f9.jpg)
Drs. Moshe Mittelman, of The Tel Aviv Sourasky Medical Center, and Drorit Merkel, of the Sheba Medical Center, both from Tel Aviv University, Israel, discuss several important presentations from the recent 2021 ASH meeti
Chien Aza – Pembro - BJH The combination of azacitidine and pembrolizumab may be a potential effective regimen for patients with higher-risk MDS and may lead to the introduction of an important class of medications into
We will discuss the addition of venetoclax to hypomethylating agents in the treatment of advanced myeloid neoplasms, especially higher-risk myelodysplastic syndromes.We will then report a study testing the efficacy and s
PAPER 1Authors: Vijenthira A. et al. (Princess Margaret, Toronto)Title: Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patientsDescription:⦁ About a third o
Bernard E et al: In the first presented study, Dr. Elza Bernard and colleagues deliver an important lesson about the high-risk mutation TP53. That is: not all of them are infeed associated with poor prognosis. Sallman DA
Dr. Amer Zeidan
Yale School of Medicine
1 appearance on this show
Dr. Nikolaos Papadantonakis
Winship Cancer Institute of Emory University
1 appearance on this show
Moshe Mittelman
The Tel Aviv Sourasky Medical Center
7 appearances on this show
Uwe Platzbecker
Leipzig
1 appearance on this show
Nicolaus Kröger
Hamburg
1 appearance on this show
Nicolaos Papadantonakis
Emory Atlanta
1 appearance on this show
Nikolaos Papadantonakis
Emory
1 appearance on this show
Prof. Rena Buckstein
Toronto
1 appearance on this show
Prof. Moshe Mittelman
Tel-Aviv
1 appearance on this show
Akiko Shimamura
Harvard Medical School
1 appearance on this show
Guillermo Sanz
Valencia
1 appearance on this show
Rafael Bejar
San Diego
1 appearance on this show
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
MDS Professional Report has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their health audience.
MDS Professional Report is hosted by MDS Foundation. The show is categorised under health (fitness) and has published 13 episodes.
MDS Professional Report has published 13 episodes.
MDS Professional Report regularly covers health, fitness, medicine. It sits in the health category, with a fitness focus.
MDS Professional Report is accessible for guests with genuine health expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
MDS Professional Report hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of MDS Professional Report average 27 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates MDS Professional Report's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 7 days ago.